Taito Esaki

10PUBLICATIONS
78CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 06, 2025
ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.

Akihito Kawazoe, Kensei Yamaguchi, Tetsuya Hamaguchi

|May 16, 2025
Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.

Hisato Kawakami, Shigenori Kadowaki, Akitaka Makiyama

|May 09, 2025
Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study.

Kentaro Sawada, Riu Yamashita, Shunsuke A Sakai

|Apr 11, 2025
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer.

Filippo Pietrantonio, Lisa Salvatore, Taito Esaki

|Aug 20, 2024
Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer.

Naoko Iida, Mitsuho Imai, Wataru Okamoto

|Aug 29, 2023
Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study.

Satoshi Yuki, Kentaro Yamazaki, Yu Sunakawa

Pageof 2

Frequent Collaborators

4 joint publications

Hideaki Bando

3 joint publications

Tadamichi Denda

3 joint publications

Kentaro Yamazaki

3 joint publications

Yoshito Komatsu